TSHA
What one share of Taysha Gene Therapies holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.
Taysha Gene Therapies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.41 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.37 |
| Cash and investments | $1.40 |
| Debt | $0.15 |
| Book value | $1.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$3.40 | $0.00 | −$1.74 | — | — |
| 2021 | — | −$4.64 | $0.41 | −$3.52 | — | — |
| 2022 | $0.06 | −$3.78 | $0.47 | −$2.48 | — | $0.01 |
| 2023 | $0.13 | −$0.96 | $0.03 | −$0.66 | — | $0.40 |
| 2024 | $0.03 | −$0.36 | $0.00 | −$0.33 | — | $0.35 |
| 2025 | $0.03 | −$0.34 | $0.00 | −$0.29 | — | $0.87 |